| Attribute |
Value |
| 52 Week Change |
-0.30331755 |
| Address1 |
117, Avenue de Luminy |
| Address2 |
BP 30191 |
| All Time High |
11.95 |
| All Time Low |
1.17 |
| Ask |
1.84 |
| Ask Size |
3 |
| Average Daily Volume10 Day |
55,350 |
| Average Daily Volume3 Month |
157,864 |
| Average Volume |
157,864 |
| Average Volume10Days |
55,350 |
| Beta |
1.188 |
| Bid |
1.54 |
| Bid Size |
1 |
| Book Value |
-0.48613393 |
| City |
Marseille |
| Compensation As Of Epoch Date |
1,767,139,200 |
| Country |
France |
| Crypto Tradeable |
0 |
| Currency |
USD |
| Current Price |
1.44 |
| Current Ratio |
0.597 |
| Custom Price Alert Confidence |
HIGH |
| Date Short Interest |
1,790,726,400 |
| Day High |
1.45 |
| Day Low |
1.44 |
| Display Name |
Innate Pharma |
| Dividend Yield |
0.0 |
| Earnings Call Timestamp End |
1,789,646,400 |
| Earnings Call Timestamp Start |
1,789,646,400 |
| Earnings Timestamp |
1,793,881,800 |
| Earnings Timestamp End |
1,793,881,800 |
| Earnings Timestamp Start |
1,793,881,800 |
| Ebitda |
-46,962,000 |
| Ebitda Margins |
0.0 |
| Enterprise To Ebitda |
-3.131 |
| Enterprise To Revenue |
14.993 |
| Enterprise Value |
147,050,096 |
| Eps Current Year |
-0.1835 |
| Eps Forward |
-0.4715 |
| Eps Trailing Twelve Months |
-0.59 |
| Esg Populated |
0 |
| Exchange |
NMS |
| Exchange Data Delayed By |
15 |
| Exchange Timezone Name |
America/New_York |
| Exchange Timezone Short Name |
EDT |
| Fax |
33 4 30 30 30 00 |
| Fifty Day Average |
1.9216 |
| Fifty Day Average Change |
-0.48159993 |
| Fifty Day Average Change Percent |
-0.25062445 |
| Fifty Two Week Change Percent |
-30.331755 |
| Fifty Two Week High |
2.71 |
| Fifty Two Week High Change |
-1.27 |
| Fifty Two Week High Change Percent |
-0.46863467 |
| Fifty Two Week Low |
1.17 |
| Fifty Two Week Low Change |
0.2700001 |
| Fifty Two Week Low Change Percent |
0.23076932 |
| Fifty Two Week Range |
1.17 - 2.71 |
| Financial Currency |
EUR |
| First Trade Date Milliseconds |
1,571,319,000,000 |
| Float Shares |
70,445,159 |
| Forward Eps |
-0.4715 |
| Forward P E |
-3.0540829 |
| Free Cashflow |
-28,962,750 |
| Full Exchange Name |
NasdaqGS |
| Full Time Employees |
120 |
| Fullday Change |
-0.029999971 |
| Fullday Change Percent |
-2.0408144 |
| Fullday Price |
1.44 |
| Gmt Off Set Milliseconds |
-14,400,000 |
| Gross Margins |
0.0 |
| Gross Profits |
-30,169,000 |
| Has Pre Post Market Data |
1 |
| Held Percent Insiders |
0.01401 |
| Held Percent Institutions |
0.00352 |
| Implied Shares Outstanding |
111,700,347 |
| Industry |
Biotechnology |
| Industry Disp |
Biotechnology |
| Industry Key |
biotechnology |
| Is Earnings Date Estimate |
0 |
| Language |
en-US |
| Last Fiscal Year End |
1,767,139,200 |
| Long Business Summary |
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma; IPH4502, a novel and differentiated topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4; and Monalizumab, a dual checkpoint inhibitor that targets T Cells and NK Cells. It also develops IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway; IPH6401, an BCMA-targeting NK cell engager; IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. In addition, the company develops IPH6501, a tetra-specific NK cell engager to activate receptors, NKp46 and CD16, tumor antigen (CD20) and an interleukin-2 receptor. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech. Innate Pharma S.A. was incorporated in 1999 and is based in Marseille, France. |
| Long Name |
Innate Pharma S.A. |
| Market |
us_market |
| Market Cap |
160,848,496 |
| Market State |
REGULAR |
| Max Age |
86,400 |
| Message Board Id |
finmb_426137 |
| Most Recent Quarter |
1,782,777,600 |
| Net Income To Common |
-47,456,000 |
| Next Fiscal Year End |
1,798,675,200 |
| Non Diluted Market Cap |
194,870,567 |
| Number Of Analyst Opinions |
3 |
| Open |
1.44 |
| Operating Cashflow |
-42,635,000 |
| Operating Margins |
-3.35705 |
| Payout Ratio |
0.0 |
| Phone |
33 4 30 30 30 30 |
| Previous Close |
1.47 |
| Price Eps Current Year |
-7.8474116 |
| Price Hint |
4 |
| Price To Book |
-2.9621468 |
| Price To Sales Trailing12 Months |
16.399725 |
| Profit Margins |
0.0 |
| Quick Ratio |
0.471 |
| Quote Source Name |
Nasdaq Real Time Price |
| Quote Type |
EQUITY |
| Recommendation Key |
none |
| Region |
US |
| Regular Market Change |
-0.029999971 |
| Regular Market Change Percent |
-2.0408144 |
| Regular Market Day High |
1.45 |
| Regular Market Day Low |
1.44 |
| Regular Market Day Range |
1.44 - 1.45 |
| Regular Market Open |
1.44 |
| Regular Market Previous Close |
1.47 |
| Regular Market Price |
1.44 |
| Regular Market Time |
1,791,989,536 |
| Regular Market Volume |
3,481 |
| Return On Assets |
-0.466 |
| Revenue Growth |
0.165 |
| Revenue Per Share |
0.105 |
| Sand P52 Week Change |
0.17004645 |
| Sector |
Healthcare |
| Sector Disp |
Healthcare |
| Sector Key |
healthcare |
| Shares Outstanding |
111,700,347 |
| Shares Percent Shares Out |
0.0008 |
| Shares Short |
88,622 |
| Shares Short Previous Month Date |
1,788,134,400 |
| Shares Short Prior Month |
81,961 |
| Short Name |
Innate Pharma S.A. |
| Short Percent Of Float |
0.0008 |
| Short Ratio |
1.92 |
| Source Interval |
15 |
| Symbol |
IPHA |
| Target High Price |
9.0 |
| Target Low Price |
4.0 |
| Target Mean Price |
6.66667 |
| Target Median Price |
7.0 |
| Total Cash |
10,896,000 |
| Total Cash Per Share |
0.116 |
| Total Debt |
20,206,000 |
| Total Revenue |
9,808,000 |
| Tradeable |
0 |
| Trailing Annual Dividend Rate |
0.0 |
| Trailing Annual Dividend Yield |
0.0 |
| Trailing Eps |
-0.59 |
| Trailing Peg Ratio |
None |
| Triggerable |
1 |
| Two Hundred Day Average |
1.731105 |
| Two Hundred Day Average Change |
-0.2911049 |
| Two Hundred Day Average Change Percent |
-0.16816133 |
| Type Disp |
Equity |
| Volume |
3,481 |
| Website |
https://www.innate-pharma.com |
| Zip |
13,009 |